Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
08 janv. 2025 09h50 HE
|
Biofrontera Inc.
Last patient completed 1 year follow-up of study ALA-BCC-CT013 in December 2024.Data from follow-up will be included in FDA submission, expected in Q3 2025.Biofrontera announced highly statistically...
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03 janv. 2025 17h20 HE
|
Palisade Bio, Inc.
Carlsbad, CA, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market
23 déc. 2024 09h30 HE
|
Biofrontera Inc.
Biofrontera started commercial distribution of the RhodoLED XL in June 2024 and has seen rapid uptake in the US market since launch.The RhodoLED XL is approved by the FDA in combination with Ameluz®...
Aridis Provides Corporate Update
20 déc. 2024 08h00 HE
|
Aridis Pharmaceuticals, Inc.
LOS GATOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on recent...
Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board
17 déc. 2024 08h30 HE
|
Palisade Bio, Inc.
Carlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules
13 déc. 2024 16h05 HE
|
Palisade Bio, Inc.
Carlsbad, CA, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules
12 déc. 2024 12h05 HE
|
Palisade Bio, Inc.
Carlsbad, CA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects
03 déc. 2024 08h15 HE
|
Palisade Bio, Inc.
First three Single Ascending Dose cohorts demonstrated no treatment related adverse events Carlsbad, CA, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,”...
Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note
22 nov. 2024 09h10 HE
|
Biofrontera Inc.
WOBURN, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization...
Greenwich LifeSciences Provides Update on Corporate Events
18 nov. 2024 06h00 HE
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an...